Eversept Partners, LP Syndax Pharmaceuticals Inc Call Options Transaction History
Eversept Partners, LP
- $1.26 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SNDX
# of Institutions
206Shares Held
88.1MCall Options Held
498KPut Options Held
76.8K-
Black Rock Inc. New York, NY7.91MShares$131 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$97.2 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$82.9 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$81.3 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.89MShares$64.7 Million1.13% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $941M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...